Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Exploiting Microbial Glycomimetics to Fight Antimicrobial Resistance

Descrizione del progetto

Combattere i batteri con gli zuccheri

Alcune infezioni comuni, come quelle delle vie urinarie, sono resistenti agli antibiotici. Questo rende il trattamento difficile e in alcuni casi impossibile. Il progetto Glyco-Biotic, sostenuto dal programma di azioni Marie Skłodowska-Curie, si concentra sul trattamento dei batteri con farmaci tradizionali. Nello specifico, sta progettando molecole a base di zucchero che imitano quelle a cui i batteri si agganciano naturalmente. Tali molecole, dette glicomimetici, possono aiutare gli antibiotici ad aderire ai batteri appropriati. Combinando questi zuccheri con antibiotici e marcatori fluorescenti, il progetto si propone di creare trattamenti più intelligenti. Una migliore diagnostica consentirà inoltre di stare un passo avanti rispetto alla resistenza antimicrobica.

Obiettivo

Antimicrobial resistance (AMR) represents a significant health and economic challenge worldwide. Due to the fact that bacterial infections affect most people at some point in their lives, methods for specific recognition and targeting of bacteria are of key importance in developing approaches to counter the growth of AMR, where the discovery of novel antibiotics represents a global challenge in urinary tract infections (UTI). Progress in bioorganic synthesis has provided access to knowledge of the interactions between receptors (lectins) and specific carbohydrate on the outer membrane of bacteria. Cell surface carboAntimicrobial resistance (AMR) represents a significant health and economic challenge worldwide, where the discovery of novel antibiotics represents a global challenge in urinary tract infections (UTI). Progress in bioorganic synthesis has provided access to knowledge of the interactions between receptors (lectins) and specific carbohydrate on the outer membrane of bacteria. It is commonly accepted that this process requires an exquisite carbohydrate specificity of bacterial surface lectins and offer an opportunity to develop very selective probes that could target specific bacteria by the development of glycan mimics as potential drug candidates. Interestingly, some bacterial strains of E. coli are specific for galabiose. In order to design a drug candidate, it will be synthesized various glycomimetics with a common core of galabiose, which will be conjugated with a fluorescence probe to evaluate their binding affinity. Our hypothesis in this project resolves around the generation of a new class of antibiotics through the combination of known antibiotic drugs with the lead glycomimetics and allowing the drug delivery to the desired location. This project aims to test both aspects of the discovery of new antibiotics employing bioorganic approach based on the design, synthesis, diagnostic assays and drug delivery analysis of appropriate molecular models.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2024-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITY OF BRISTOL
Contributo netto dell'UE
€ 260 347,92
Indirizzo
BEACON HOUSE QUEENS ROAD
BS8 1QU BRISTOL
Regno Unito
Regione
South West (England) Gloucestershire, Wiltshire and Bristol/Bath area Bristol, City of
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato